Genetic Testing Market Size and Forecast 2025–2033

Introduction

The healthcare industry is undergoing a profound transformation, driven by data, biotechnology, and the growing demand for personalized medicine. At the center of this shift lies genetic testing—a powerful tool that decodes DNA to predict disease risks, guide targeted therapies, and improve preventive care. What was once confined to specialized laboratories is now becoming a routine part of clinical diagnostics, oncology, prenatal screening, and even consumer wellness.

According to Renub Research, the global genetic testing market is projected to grow from USD 21.47 billion in 2024 to approximately USD 49.72 billion by 2033, expanding at a robust CAGR of 9.79% between 2025 and 2033. This growth reflects not only technological innovation but also a paradigm shift in how healthcare systems approach diagnosis, treatment, and long-term patient management.

Download Free Sample Report

From cancer genomics and rare disease diagnostics to ancestry testing and pharmacogenomics, genetic testing is redefining modern medicine. This article explores the market outlook, key players, innovations, sustainability initiatives, and the strategic forces shaping the future of genetic testing worldwide.

Understanding the Genetic Testing Market

Genetic testing refers to medical tests that analyze an individual’s DNA, genes, chromosomes, or proteins to identify inherited conditions, disease predispositions, and potential responses to treatment. These tests can confirm diagnoses, assess risk for future illness, inform reproductive planning, and guide personalized therapies.

Over the past decade, genetic testing has moved beyond traditional hospital settings. Advances in next-generation sequencing (NGS), automation, digital bioinformatics, and artificial intelligence have reduced costs while increasing speed and accuracy. Meanwhile, the rise of direct-to-consumer (DTC) genetic tests has made genomic insights accessible to individuals without a physician’s referral.

More importantly, healthcare is increasingly shifting toward precision medicine—treating patients based on their unique genetic makeup rather than using standardized protocols. Genetic testing enables clinicians to select optimal drugs, minimize adverse effects, and predict disease progression. As a result, genomics is no longer a niche discipline; it is becoming a foundational pillar of 21st-century medicine.

Market Size and Forecast: 2025–2033

Renub Research estimates that the genetic testing market will reach USD 49.72 billion by 2033, up from USD 21.47 billion in 2024, driven by a 9.79% compound annual growth rate. This expansion is fueled by three core application areas:

Oncology:

Genetic profiling of tumors enables targeted therapies, immuno-oncology, and personalized treatment regimens. Liquid biopsies, companion diagnostics, and somatic mutation analysis are revolutionizing cancer care.

Rare Disease Diagnostics:

Whole genome and exome sequencing are accelerating the diagnosis of rare and inherited disorders that previously took years to identify, improving patient outcomes and reducing healthcare costs.

Prenatal and Reproductive Testing:

Non-invasive prenatal testing (NIPT), carrier screening, and embryo genetic analysis are increasingly used in fertility clinics and obstetric care.

In addition to clinical applications, consumer genomics, pharmacogenomics, and population screening programs are expanding the market footprint. Governments and healthcare systems worldwide are integrating genomics into national health strategies, reinforcing long-term market growth.

Top 5 Companies in the Genetic Testing Market by 2033

1. Abbott Laboratories (USA)

Founded: 1888 | Headquarters: United States

Abbott Laboratories is a global leader in diagnostics, medical devices, and healthcare solutions. Its genetic testing presence is supported by a broad portfolio of laboratory systems, point-of-care diagnostics, molecular testing platforms, and automation solutions. Abbott’s strength lies in its global distribution network and its ability to integrate genetic testing into routine clinical workflows across hospitals, research labs, and government health systems.

2. Illumina Inc. (USA)

Founded: 1998 | Headquarters: San Diego, California

Illumina is synonymous with DNA sequencing technology. Its integrated systems for genomic analysis power research centers, pharmaceutical companies, and clinical labs worldwide. A notable recent move includes its December 2023 partnership with aploX in China, enabling local manufacturing of sequencing instruments. This strengthens Illumina’s presence in Asia and accelerates access to advanced genomics.

3. Roche Ltd. (Switzerland)

Founded: 1896 | Headquarters: Basel

Roche operates across pharmaceuticals and diagnostics, with a strong focus on oncology, immunology, and infectious diseases. The company has consistently aligned genetic testing with therapeutic development, enabling companion diagnostics that match patients with targeted drugs. Roche’s inclusion of numerous medicines on the WHO Essential Medicines List highlights its impact on global healthcare.

4. Thermo Fisher Scientific (USA)

Founded: 2006 | Headquarters: United States

Thermo Fisher provides analytical instruments, molecular biology tools, and specialty diagnostics under brands such as Applied Biosystems, Thermo Scientific, and Fisher Scientific. Serving pharmaceutical companies, academic institutions, and government labs, the company plays a critical role in genomic research, clinical diagnostics, and biotechnology innovation.

5. Danaher Corporation (USA)

Founded: 1984 | Headquarters: United States

Danaher is a science and technology powerhouse delivering advanced diagnostic tools, genomic consumables, flow cytometers, mass spectrometry reagents, and lab automation systems. Its life sciences portfolio supports precision medicine, research laboratories, and healthcare facilities worldwide.

Notable Product Launches and Strategic Collaborations

Bio-Rad Laboratories Inc. (June 2024)

Bio-Rad launched the ddSEQ™ Single-Cell 3' RNA-Seq Kit alongside Omnition v1.1 software, enabling efficient single-cell transcriptome research. The platform enhances gene expression analysis in oncology, neurology, immunology, and stem cell research—strengthening Bio-Rad’s footprint in next-generation genomics.

Myriad Genetics & SOPHiA GENETICS (September 2025)

Myriad Genetics partnered with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) solution for pharmaceutical companies. Leveraging Myriad’s U.S. laboratory expertise and SOPHiA’s decentralized global network, this collaboration expands precision oncology across clinical trials worldwide.

SWOT Insights: Competitive Positioning

Diasorin – Strength: Molecular Diagnostics Leadership

Diasorin’s strength lies in its advanced molecular diagnostics platforms, particularly nucleic acid amplification and automation. Its LIAISON® MDX systems enable high-throughput genetic analysis across oncology, infectious diseases, and hereditary disorders. With strong R&D and global distribution, Diasorin is well-positioned to lead next-generation genetic testing.

Quest Diagnostics – Strength: Scale and Clinical Genomics Leadership

Quest Diagnostics benefits from one of the world’s largest diagnostic networks. Its genetic testing services span hereditary disease screening, oncology genomics, and pharmacogenomics. By integrating digital health platforms and partnering with biopharmaceutical firms, Quest continues to expand access to personalized healthcare.

Recent Market Developments

Revvity Inc. (January 2025)

Revvity partnered with Element Biosciences to commercialize an IVD workflow for neonatal sequencing, supporting regulatory approval for the AVITI™ sequencing system. This initiative enhances early-life diagnostics and expands access to automated NGS solutions.

QIAGEN N.V. (April 2025)

QIAGEN introduced new QIAseq panels for comprehensive genomic profiling, a new QIAcuity digital PCR kit, and advanced bioinformatics tools through its Digital Insights division. These developments strengthen cancer genomic profiling and cell and gene therapy research.

Sustainability and ESG in Genetic Testing

Laboratory Corporation of America Holdings (Labcorp)

Labcorp is committed to achieving net-zero greenhouse gas emissions by 2050 through energy-efficient laboratories, renewable energy adoption, and waste reduction. The company also focuses on health equity, patient access, employee well-being, and ethical governance—aligning innovation with social responsibility.

Eurofins Scientific SE

Eurofins aims for carbon neutrality by 2050, emphasizing green laboratory practices, waste minimization, and renewable energy. Its analytical testing services support sustainable agriculture, environmental protection, and clean energy initiatives, reinforcing ESG compliance across global operations.

Market Segmentation and Competitive Landscape

The genetic testing market is segmented by:

Technology: Next-generation sequencing, PCR, microarrays, and bioinformatics

Application: Oncology, rare diseases, prenatal testing, pharmacogenomics, ancestry

End-User: Hospitals, diagnostic laboratories, research institutions, consumer genomics

Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Market share remains competitive, with leading companies investing in automation, AI-driven analytics, cloud-based genomic platforms, and strategic acquisitions to expand product portfolios and geographic reach.

Strategic Outlook: Where the Market Is Headed

Several macro trends will define the future of genetic testing:

Integration of AI and Bioinformatics

Artificial intelligence is enhancing variant interpretation, accelerating diagnosis, and reducing analysis time.

Growth of Liquid Biopsy and Non-Invasive Testing

Blood-based genetic testing is transforming cancer diagnostics and treatment monitoring.

Expansion in Emerging Markets

Asia-Pacific, Latin America, and the Middle East are witnessing increased investments in genomics infrastructure and healthcare digitization.

Policy and Reimbursement Support

Governments are increasingly recognizing genomics as a core healthcare service, improving reimbursement and accessibility.

Consumer Empowerment and Preventive Healthcare

Direct-to-consumer genetic testing continues to expand, encouraging proactive health management and lifestyle personalization.

Final Thoughts

The genetic testing market is no longer confined to research laboratories or specialized clinics—it is rapidly becoming a cornerstone of global healthcare. With the market projected to grow from USD 21.47 billion in 2024 to USD 49.72 billion by 2033, driven by a 9.79% CAGR, genetic testing is reshaping how diseases are diagnosed, treated, and prevented.

Advancements in sequencing technologies, the rise of precision medicine, and the expansion of consumer genomics are accelerating adoption across clinical, research, and personal health domains. At the same time, industry leaders such as Abbott, Illumina, Roche, Thermo Fisher, and Danaher continue to innovate through strategic partnerships, sustainability initiatives, and digital integration.

As healthcare moves toward personalized, predictive, and preventive models, genetic testing will remain at the forefront—bridging science and everyday medicine. The coming decade will not only expand the market but redefine the very foundations of modern healthcare, making genomics an essential tool for a healthier, more informed global population.